CARsgen Therapeutics Receives IND Clearance for GPC3-CAR-T Cells from the NMPA

News provided by

CARsgen Therapeutics Co. Ltd.

29 Jan, 2019, 05:00 ET

SHANGHAI, Jan. 29, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, humanized GPC3-CAR-T cell for the treatment of patients suffering from GPC3-positive solid tumors, has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA). This marks China's first IND clearance for CAR-T cells against solid tumors.

"The IND clearance of GPC3-CAR-T cells by China's NMPA is of great significance to CARsgen," said Dr. Zonghai Li, founder, CEO and CSO of CARsgen. "Solid tumors, particularly hepatocellular carcinoma, represent major health challenges due to increasing incidence and limited available therapeutic solutions. In China, the estimated annual incidence of HCC has already reached 467,000[1]. While in the U.S., HCC is also a leading cause of death with 37,948 new cases every year [2]. To cope with the situation, we plan to submit IND Application for GPC3-CAR-T cells to FDA by the end of 2019. Our goal is to continue the development of novel, safe and effective immunotherapies. This is our long-standing commitment to cancer patients worldwide."

References:

About CARsgen Therapeutics

CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development and commercialization of CAR-T therapeutics for unmet medical need. The company has launched several First-in-Human CAR-T clinical trials to treat relapsed/refractory tumors, including CAR-GPC3-T for hepatocellular carcinoma and squamous lung cancer, CAR-EGFR/EGFRvIII-T for glioblastoma multiforme and CAR-Claudin18.2-T for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs of humanized CAR-CD19-T for acute lymphocyte leukemia and fully humanized CAR-BCMA-T program for multiple myeloma.

For more information, please visit: www.carsgen.com

SOURCE CARsgen Therapeutics Co. Ltd.

Related Links

http://www.carsgen.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.